|
Management Dr Paul Harper, ChairmanDr Paul Harper has over 30 years' experience in the life sciences industry covering both drug development and medical devices. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications. Dr Christophe Chassagnole, Chief Operating Officer Dr Christophe Chassagnole has been involved in Systems Biology projects during the 10 last years, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the company. He was appointed Chief Operating Officer of Physiomics in May 2007. Mr Roger Jones, Financial Controller and Company Secretary Mr. Jones has for 30 years been a Fellow of the Association of Chartered Certified Accountants and has held a number of senior financial positions and key roles in biotechnology and pharmaceutical companies including Cambridge Antibody Technology, Onyvax, Archimedes Pharma, Angel Biotechnology and Provensis.
Scientific Advisory Board The Scientific Advisory Board (‘‘SAB’’) is responsible for critically reviewing the Group’s scientific strategy. Its role will be to inform the Group of any scientific or technological advances that are relevant to Physiomics or its competitors, and provide links to a network of business, industrial and academic contacts. The SAB will convene as required and its membership will be reviewed periodically.Professor David Fell , is the Chairman of the SAB. He is Assistant Dean of the School of Biological and Molecular Sciences at Oxford Brookes University and is recognised as an expert in systems biology. Professor Fell runs a research team at Oxford Brookes University where current projects include the analysis of the structure of metabolic networks, the computer simulation of signal transduction and elementary modes for the analysis of metabolism and metabolic engineering. He is the author or co-author of approximately 85 scientific publications and has written one of the standard textbooks, ‘‘Understanding the Control of Metabolism’’ in the area of metabolic control analysis. Professor Fell has been involved with the Company since 2001. Professor Marta Cascante , of the University of Barcelona, is an expert on systems biology and the development of metabolic simulations. She has a long standing interest in the metabolism of cancer cells. Professor Tom Cotter , currently Professor of Biochemistry at the University of Cork, is an expert in the field of apoptosis and member of a number of governmental and non governmental scientific advisory bodies.
|
|
|
|||||||||||||||||